Marex Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Marex Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.27M	Buy	27,000 +19,000	+238%	+$2.57M	0.02%	274
2026 Q1	$1.02M	Sell	8,000 -7,000	-47%	-$874K	0.01%	431
2025 Q4	$1.83M	Buy	15,000 +7,500	+100%	+$860K	0.01%	325
2025 Q3	$752K	Sell	7,500 -12,500	-63%	-$1.13M	0.01%	406
2025 Q2	$1.66M	Buy	+20,000	New	+$1.6M	0.01%	243

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Marex Group's XBI Position: Q2 2026 in Review

Marex Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 3,588 shares — an estimated $485K sold.

Marex Group first reported a position in XBI in Q2 2023 and held it in 8 quarters. The position peaked at $2.36M in Q3 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Marex Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Marex Group sold 3,588 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $485K.
Marex Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and held it in 8 quarters.
Marex Group's State Street SPDR S&P Biotech ETF position peaked at $2.36M in Q3 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.